SPOTLIGHT -
Dr Meyer is a voluntary clinical professor of psychiatry at the University of California, San Diego.
Demystifying Lithium Therapy—A Primer for Clinicians: Lithium-Related Polyuria, Part 2
In this CME article, learn more about alternative methods to screen for lithium-related polyuria and how to implement amiloride for lithium-related polyuria.
Demystifying Lithium Therapy—A Primer for Clinicians: Renal Issues, Part 1
In this CME article, learn more about recent developments with lithium as they relate to renal issues.
Questions and Answers About Clozapine, Part 2: A Dialogue About Indications for Clozapine, Managing Adverse Effects, and More
In this CME article, review management of several clozapine-related adverse effects and outline considerations when addressing inadequate positive symptom response to clozapine.
Questions and Answers About Clozapine: A Dialogue About the Use of Plasma Levels
In this CME article, read more about best practices for utilizing clozapine plasma levels and the clozapine/norclozapine ratio to monitor clozapine therapy.
Lithium Undervalued? A Conversation With Jonathan M. Meyer, MD
Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.
Appropriate Treatment for Treatment-Resistant Schizophrenia
Which treatment approaches are the state-of-the-art for helping this patient population?
The Metabolic Syndrome and Schizophrenia: Clinical Research Update
Glucose Dysregulation
The atypical antipsychotics have become the treatment of choice for patients with psychotic and other behavioral disorders. However, case reports, retrospective studies and epidemiological data suggest that these medications may be associated with new-onset type 2 diabetes and diabetic ketoacidosis.